Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies, has recieved a $1.5 million milestone payment from Lummy Co. Ltd. of Hong Kong.    The milestone payment was made in consideration of the successful initiation of technology transfer related to the manufacturing of Rocapuldencel-T to Lummy by the Company, to which Lummy has a license for commercialization in these territories.    “We appreciate L...